MRK241213C102000
- 0.16
- -0.35-68.63%
Merck & Co Newsroom
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
Express News | Lynparza® (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in Olympia Phase 3 Trial
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
BofA Restarts Coverage of 11 Large-cap Biopharmas
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
10 Health Care Stocks With Whale Alerts In Today's Session
Dow Down 150 Points On Losses For Shares Of Caterpillar, 3M
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Today's Analyst Rating | Tesla Price Target Raised to $400 by Morgan Stanley, Oracle Price Target Raised to $194 by Citi
Dec 10, Wall Street analysts have updated their stock ratings today including $Tesla(TSLA.US)$ and $Oracle(ORCL.US)$.
B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target
Merck & Co Analyst Ratings
Ideaya Biosciences Has Dosed The First Patient In Phase 1 Trial Evaluating The Combination Of IDE161 In Combination With Merck's Keytruda (Pembrolizumab), In Endometrial Cancer Patients With High Microsatellite Instability And Microsatellite Stable
Express News | Merck's PD-1 inhibitor, Keytruda, has been approved for the treatment of locally advanced cervical cancer in China.
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck Reports Positive Phase 2 Data for Zilovertamab Vedotin
Merck's Keytruda Combined With Chemotherapy and Lynparza Regimen Meets Phase 3 Primary Endpoint